title: Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
abstract: In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
authors.affiliation: The Kirby Institute, University of New South Wales Australia, Sydney.
authors.forename: Jason
authors.initials: J
authors.lastname: Grebely
authors.affiliation: The Kirby Institute, University of New South Wales Australia, Sydney.
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Dore
authors.affiliation: Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.affiliation: Portsmouth Hospitals NHS Trust, Portsmouth.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Aspinall
authors.affiliation: Brownlee Centre, Glasgow, United Kingdom.
authors.forename: Raymond
authors.initials: R
authors.lastname: Fox
authors.affiliation: Gilead Sciences, Inc., Foster City, California.
authors.forename: Lingling
authors.initials: L
authors.lastname: Han
authors.affiliation: Gilead Sciences, Inc., Foster City, California.
authors.forename: John
authors.initials: J
authors.lastname: McNally
authors.affiliation: Gilead Sciences, Inc., Foster City, California.
authors.forename: Anu
authors.initials: A
authors.lastname: Osinusi
authors.affiliation: Gilead Sciences, Inc., Foster City, California.
authors.forename: Diana M
authors.initials: DM
authors.lastname: Brainard
authors.affiliation: Gilead Sciences, Inc., Foster City, California.
authors.forename: G Mani
authors.initials: GM
authors.lastname: Subramanian
authors.affiliation: Gilead Sciences, Inc., Foster City, California.
authors.forename: Macky
authors.initials: M
authors.lastname: Natha
authors.affiliation: Queen Mary University London, United Kingdom.
authors.forename: Graham R
authors.initials: GR
authors.lastname: Foster
authors.affiliation: Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mangia
authors.affiliation: Johns Hopkins University, Baltimore, Maryland.
authors.forename: Mark
authors.initials: M
authors.lastname: Sulkowski
authors.affiliation: Toronto Centre for Liver Disease, Ontario, Canada.
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Feld
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002219:Carbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006576:Heterocyclic Compounds, 4 or More Rings / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D058850:Opiate Substitution Treatment; D012254:Ribavirin / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000072230:Sustained Virologic Response; D016896:Treatment Outcome; D001562:Benzimidazoles; D001578:Benzopyrans
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D006576:Heterocyclic Compounds, 4 or More Rings; D012254:Ribavirin; D000069474:Sofosbuvir; C000604171:velpatasvir; D001562:Benzimidazoles; D001578:Benzopyrans
keywords: HCV; OST; PWID; sofosbuvir; velpatasvir